This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Comparison of Hypophysectomy, Replacement Therapy, Estrogens, and Androgens

JOSEPH A. WITT, M.D.; BERNARD GARDNER, M.D.; GILBERT S. GORDAN, M.D., Ph.D.; WILLIAM P. GRAHAM III, M.D.; ARTHUR N. THOMAS, M.D.

Arch Intern Med. 1963;111(5):557-563.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

When breast cancer spreads beyond control by surgical or roentgen therapy, regressions can still be produced by the administration of hormones, endocrine ablative procedures, or by chemotherapy. In postmenopausal women estrogens and androgens produce objective regressions as primary hormonal therapy in 20% to 30% of all cases^* When such primary therapy ceases to be effective, or if the disease fails to respond to it, secondary hormonal therapy generally produces fewer objective regressions. The purpose of this study is to compare the antitumor efficacy of various secondary hormonal treatments in advanced breast cancer and to attempt to ascertain whether regressions obtained from hypophysectomy are due to the removal of pituitary factors or to hormonal replacement therapy.

Method

All postmenopausal women with objectively progressing disseminated breast cancer previously treated by hormonal therapy under the protocol of the Cooperative Breast Cancer Study Group¹ or referred to us after hormonal therapy had been . . . [Full Text PDF of this Article]

Author Affiliations
SAN FRANCISCO

From the Departments of Neurological Surgery, Surgery, and Medicine of the University of California Medical Center.; Assistant Professor of Neurological Surgery (Dr. Witt), Assistant Resident in Surgery (Dr. Gardner), Associate Professor of Medicine (Dr. Gordan), Graduate Research Surgeon (Dr. Graham), and Assistant Resident in Surgery (Dr. Thomas), University of California School of Medicine.

Footnotes
Received for publication Aug. 6, 1962; accepted Sept. 19.

Aided by an institutional grant from the American Cancer Society and U.S. Public Health Service Grant CYP-3489.

Prednisone and hydrocortisone were supplied by Dr. Elmer Alpert, Merck Sharp & Dohme, North Wales, Pa., and Dr. Harold Upjohn, The Upjohn Company, Kalamazoo, Mich.; sodium liothyronine by Mr. William Kirsch, Smith, Kline & French, Philadelphia; 2--methyldihydrotestosterone propionate by Dr. Harry Rudel, Syntex Laboratories, New York, and Dr. Glenn Irwin, Eli Lilly Company, Indianapolis; these and other compounds were provided by the Cancer Chemotherapy National Service Center, Bethesda, Md., under whose protocol and auspices this study was carried out. Each case was reviewed by 2 or more of the following extramural referees, to whom we express our appreciation: Drs. Harry F. Bisel, Charles M. Blackburn, George C. Escher, Robert A. Huseby, Robert G. Ravdin, and Albert Segaloff. Dr. Edwin B. Boldrey kindly permitted us to include data from 2 of his patients.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?